Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors, World Journal of Oncology, vol.10, issue.1, pp.10-27, 2019. ,
Focus on an unusual rise in pancreatic cancer incidence in France, International Journal of Epidemiology, vol.46, issue.6, pp.1764-1772, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01541663
More deaths from pancreatic cancer than breast cancer in the EU by 2017, Acta Oncologica, vol.55, issue.9-10, pp.1158-1160, 2016. ,
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, New England Journal of Medicine, vol.364, issue.19, pp.1817-1825, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00598658
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer, New England Journal of Medicine, vol.379, issue.25, pp.2395-2406, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02281628
Serum CA 19-9 as a Biomarker for Pancreatic Cancer?A Comprehensive Review, Indian Journal of Surgical Oncology, vol.2, issue.2, pp.88-100, 2011. ,
Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan, Hepatogastroenterology, vol.53, issue.67, pp.1-4, 2006. ,
Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population, Journal of Gastroenterology and Hepatology, vol.19, issue.2, pp.182-186, 2004. ,
Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC), Digestive and Liver Disease, vol.50, issue.12, pp.1257-1271, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02143547
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas ? A retrospective tumor marker prognostic study, International Journal of Surgery, vol.11, issue.10, pp.1067-1072, 2013. ,
Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma, Pancreatology, vol.17, issue.1, pp.95-102, 2017. ,
Utility of Tumor Markers in Determining Resectability of Pancreatic Cancer, Archives of Surgery, vol.138, issue.9, p.951, 2003. ,
Prognostic Factors in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy, Pancreas, vol.12, issue.3, pp.267-271, 1996. ,
Liquid biopsies come of age: towards implementation of circulating tumour DNA, Nature Reviews Cancer, vol.17, issue.4, pp.223-238, 2017. ,
Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA, Cancer Discovery, vol.4, issue.6, pp.650-661, 2014. ,
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, Cell, vol.53, issue.4, pp.549-554, 1988. ,
Cancer biomarkers: Written in blood, 2003. ,
Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma, International Journal of Cancer, vol.146, issue.5, pp.1445-1456, 2019. ,
Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker, Clinical Cancer Research, vol.23, issue.1, pp.116-123, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01458933
Detecting biomarkers with microdroplet technology, Trends in Molecular Medicine, vol.18, issue.7, pp.405-416, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299585
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA, Science Translational Medicine, vol.4, issue.136, pp.136ra68-136ra68, 2012. ,
Screening for Pancreatic Cancer, JAMA, vol.322, issue.5, p.438, 2019. ,
Distant metastasis occurs late during the genetic evolution of pancreatic cancer, Nature, vol.467, issue.7319, pp.1114-1117, 2010. ,
Mechanisms of Disease: chronic inflammation and cancer in the pancreas?a potential role for pancreatic stellate cells?, Nature Clinical Practice Gastroenterology & Hepatology, vol.4, issue.8, pp.454-462, 2007. ,
KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control, Oncotarget, vol.7, issue.48, pp.78827-78840, 2016. ,
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers, Proceedings of the National Academy of Sciences, vol.114, issue.38, pp.10202-10207, 2017. ,
Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer, Advances in Experimental Medicine and Biology, vol.924, pp.13-17, 2016. ,
Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer, Clinical Chemistry, vol.62, issue.11, pp.1482-1491, 2016. ,
High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients, Annals of Oncology, vol.28, issue.4, pp.741-747, 2017. ,
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients, Nature Communications, vol.6, issue.1, p.7686, 2015. ,
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nature Medicine, vol.20, issue.4, pp.430-435, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02362372
Circulating Tumor DNA Outperforms Circulating Tumor Cells for KRAS Mutation Detection in Thoracic Malignancies, Clinical Chemistry, vol.61, issue.10, pp.1299-1304, 2015. ,
Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer, Oncotarget, vol.8, issue.50, pp.87221-87233, 2017. ,
Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood, Clinical Epigenetics, vol.11, issue.1, p.59, 2019. ,
Basic techniques in endoscopic ultrasound-guided fine needle aspiration for solid lesions: Adverse events and avoiding them, Endosc. Ultrasound, vol.3, issue.1, pp.35-45, 2014. ,
Diagnostic potency of EUS-guided FNA for the evaluation of pancreatic mass lesions, Endoscopic Ultrasound, vol.5, issue.1, p.30, 2016. ,
Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine, Cancers, vol.11, issue.8, p.1152, 2019. ,
DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES, Neuro-Oncology, vol.16, issue.suppl 3, pp.iii7-iii7, 2014. ,
Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue, Pancreatology, vol.17, issue.2, pp.285-290, 2017. ,
Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer, Journal of Hematology & Oncology, vol.12, issue.1, p.130, 2019. ,
Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer, Gastroenterology, vol.156, issue.1, pp.108-118.e4, 2019. ,
Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma, Oncotarget, vol.8, issue.58, pp.97769-97786, 2017. ,
Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma, Clinical Chemistry, vol.64, issue.4, pp.726-734, 2018. ,
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.9, issue.5, pp.1211-1219, 2018. ,
Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy, Cancer Science, vol.111, issue.1, pp.266-278, 2019. ,
Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer, Clinical Cancer Research, vol.25, issue.16, pp.4973-4984, 2019. ,
A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative, Oncotarget, vol.8, issue.48, pp.83446-83456, 2016. ,
Methylation profile of circulating plasma DNA in patients with pancreatic cancer, Journal of Surgical Oncology, vol.99, issue.2, pp.119-122, 2009. ,
Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer, Oncotarget, vol.9, issue.2, pp.2076-2085, 2017. ,
Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients, Scientific Reports, vol.8, issue.1, p.11631, 2018. ,
Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer, EBioMedicine, vol.41, pp.345-356, 2019. ,
Multiplex Enrichment and Detection of Rare KRAS Mutations in Liquid Biopsy Samples using Digital Droplet Pre-Amplification, Analytical Chemistry, vol.91, issue.12, pp.7516-7523, 2019. ,
Detection ofK-rasgene mutation by liquid biopsy in patients with pancreatic cancer, Cancer, vol.121, issue.13, pp.2271-2280, 2015. ,
Progression of Chronic Pancreatitis to Pancreatic Cancer, Pancreas, vol.47, issue.2, pp.227-232, 2018. ,
Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours, British Journal of Cancer, vol.117, issue.7, pp.1017-1025, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02377819
A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer, Theranostics, vol.9, issue.5, pp.1280-1287, 2019. ,
Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma, Clinical Epigenetics, vol.8, issue.1, p.117, 2016. ,
Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis, Cancer, vol.116, issue.7, pp.1674-1680, 2010. ,
Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis, Scientific Reports, vol.9, issue.1, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02408835
Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer, PLOS ONE, vol.14, issue.12, p.e0227366, 2019. ,
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer, Annals of Oncology, vol.30, issue.9, pp.1472-1478, 2019. ,
KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study, British Journal of Cancer, vol.118, issue.5, pp.662-669, 2018. ,
K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer, European Journal of Surgical Oncology (EJSO), vol.36, issue.7, pp.657-662, 2010. ,
Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer, Molecular Oncology, vol.10, issue.4, pp.635-643, 2015. ,
Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis, Gene, vol.679, pp.328-334, 2018. ,
Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer., Journal of Clinical Oncology, vol.32, issue.15_suppl, pp.4025-4025, 2014. ,
Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer, PLOS ONE, vol.12, issue.1, p.e0169736, 2017. ,
Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results, International Journal of Clinical Oncology, vol.20, issue.3, pp.518-524, 2014. ,
Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring, The Oncologist, vol.23, issue.5, pp.566-572, 2018. ,
Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring, The Oncologist, vol.23, issue.5, pp.566-572, 2018. ,
Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients, International Journal of Cancer, vol.140, issue.10, pp.2344-2350, 2017. ,
Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer, Scientific Reports, vol.9, issue.1, 2019. ,
Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer, Journal of Translational Medicine, vol.16, issue.1, p.300, 2018. ,
High Levels of Cell-Free Circulating Nucleic Acids in Pancreatic Cancer are Associated With Vascular Encasement, Metastasis and Poor Survival, Cancer Investigation, vol.33, issue.3, pp.78-85, 2015. ,
Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients., Journal of Clinical Oncology, vol.37, issue.15_suppl, pp.4136-4136, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02413138
Promoter hypermethylation in plasma-derived cell-free DNA as a prognostic marker for pancreatic adenocarcinoma staging, International Journal of Cancer, vol.141, issue.12, pp.2489-2497, 2017. ,
Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma, Oncotarget, vol.8, issue.55, pp.93942-93956, 2017. ,
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer, Scientific Reports, vol.7, issue.1, p.7931, 2017. ,
Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.29, issue.12, pp.39-50, 2017. ,
Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations, Clinical Cancer Research, vol.24, issue.6, pp.1326-1336, 2018. ,
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.38, issue.1, pp.317-327, 2019. ,
NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma, Clinical Cancer Research, vol.25, issue.15, p.clincanres.0191.2019, 2019. ,
Allelic imbalance and microsatellite instability in plasma DNA released from polyclonal pancreatic adenocarcinoma, International Journal of Oncology, vol.21, issue.5, pp.949-956, 2002. ,
Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma, Cancer Biology & Therapy, vol.20, issue.10, pp.1348-1353, 2019. ,
Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer, British Journal of Cancer, vol.115, issue.1, pp.59-65, 2016. ,
Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA, British Journal of Cancer, vol.87, issue.5, pp.551-554, 2002. ,